BioSpace News Archive

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Adora Ndu, Pharm.D., J.D. to its Board of Directors.

Solid Biosciences, a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today reported additional positive one-year data from the IGNITE DMD Phase I/II clinical trial of its microdystrophin gene therapy, SGT-001, for the functional endpoint of stride velocity 95th centile (SV95C).

Cipher Skin, the hardware-enabled monitoring platform that delivers flexible, hybrid recovery for musculoskeletal care, today announces it has launched an integration with Medistics, a care management platform that aggregates patient health data for more personalized, holistic care delivery.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the completion of enrollment in the Phase 3 PATHFNDR-1 study. PATHFNDR-1 is one of two ongoing, placebo-controlled Phase 3 studies evaluating the safety and efficacy of once-daily oral paltusotine in acromegaly patients.

InMode Ltd. announced that it expects to release its financial results for the third quarter of 2022 before the Nasdaq market opens on Thursday, October 27, 2022.

Braille Institute announced that the Organization’s Board of Directors has named James P. Kales as Chief Executive Officer.

Insmed Incorporated today announced that it will release its third quarter 2022 financial results on Thursday, October 27, 2022.

Obatala Sciences today announced the closing of a $3 million Series A finance round co-led by être Venture Capital and Ochsner Lafayette General Healthcare Innovation Fund II and joined by Benson Capital Partners, Elevate Capital Fund, and The Hackett-Robertson-Tobe Group.

Pandemic Response Lab (PRL), a wholly owned subsidiary of Opentrons Labworks, Inc., today announced two new three-target monkeypox tests , each developed and performed by its New York and Maryland laboratories, respectively.

Maze Therapeutics today announced that Harold Bernstein, M.D., Ph.D., a 30-year industry veteran, has been appointed as president, head of research and development (R&D) and chief medical officer.